DE60008753D1 - Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen - Google Patents
Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungenInfo
- Publication number
- DE60008753D1 DE60008753D1 DE60008753T DE60008753T DE60008753D1 DE 60008753 D1 DE60008753 D1 DE 60008753D1 DE 60008753 T DE60008753 T DE 60008753T DE 60008753 T DE60008753 T DE 60008753T DE 60008753 D1 DE60008753 D1 DE 60008753D1
- Authority
- DE
- Germany
- Prior art keywords
- anxieties
- treatment
- naaladase inhibitors
- memory disorder
- anxiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000026139 Memory disease Diseases 0.000 title 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000003958 Glutamate Carboxypeptidase II Human genes 0.000 abstract 1
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/345,782 US6228888B1 (en) | 1999-07-01 | 1999-07-01 | Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors |
| PCT/US2000/018260 WO2001001974A2 (en) | 1999-07-01 | 2000-06-30 | Naaladase inhibitors in anxiety and memory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60008753D1 true DE60008753D1 (de) | 2004-04-08 |
Family
ID=23356457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60008753T Expired - Lifetime DE60008753D1 (de) | 1999-07-01 | 2000-06-30 | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US6228888B1 (de) |
| EP (1) | EP1202717B1 (de) |
| JP (1) | JP2003503451A (de) |
| AT (1) | ATE260653T1 (de) |
| AU (2) | AU5785100A (de) |
| CA (1) | CA2378467A1 (de) |
| DE (1) | DE60008753D1 (de) |
| MX (1) | MXPA02000255A (de) |
| WO (1) | WO2001001974A2 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6025344A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Certain dioic acid derivatives useful as NAALADase inhibitors |
| CZ200113A3 (cs) * | 1998-07-06 | 2001-08-15 | Guilford Pharmaceuticals Inc. | Inhibitory NAALAdázy využitelné jako léčiva a farmaceutické kompozice, které je obsahují |
| US6395718B1 (en) | 1998-07-06 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors |
| US6444657B1 (en) | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
| US6479470B1 (en) | 1999-04-28 | 2002-11-12 | Georgetown University | Ligands for metabotropic glutamate receptors and inhibitors of NAALAdase |
| US6528499B1 (en) | 2000-04-27 | 2003-03-04 | Georgetown University | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase |
| WO2001092273A2 (en) * | 2000-05-30 | 2001-12-06 | Guilford Pharmaceuticals Inc. | Benzenedicarboxylic acid derivatives |
| US7220780B2 (en) | 2000-05-30 | 2007-05-22 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors for treating retinal disorders and glaucoma |
| WO2003057670A2 (en) * | 2001-12-28 | 2003-07-17 | Guilford Pharmaceuticals Inc. | Indoles as naaladase inhibitors |
| US20030162694A1 (en) * | 2002-02-04 | 2003-08-28 | James Meyerhoff | Novel treatment for pathological aggression |
| CA2518234C (en) | 2003-03-03 | 2012-11-13 | Guilford Pharmaceuticals Inc. | Thiolactones |
| EP1867330A4 (de) * | 2005-03-30 | 2012-01-25 | Kyowa Hakko Bio Co Ltd | Verfahren zur verbesserung der lagerstabilität einer substanz |
| LT2982372T (lt) | 2005-04-05 | 2020-10-26 | Yale University | Glutamatą moduliuojantys agentai psichikos sutrikimų gydymui |
| ES2547481T3 (es) | 2006-11-08 | 2015-10-06 | Molecular Insight Pharmaceuticals, Inc. | Heterodímeros de ácido glutámico |
| WO2010065899A2 (en) | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof |
| BR112012000210A2 (pt) | 2009-06-15 | 2019-09-24 | Molecular Insight Pharm Inc | processo para a produção de heterodímeoros de ácido glutâmico. |
| EP2338892A1 (de) | 2009-12-18 | 2011-06-29 | Bayer Schering Pharma Aktiengesellschaft | Prostataspezifische Membranantigen-Inhibitoren |
| US9737552B2 (en) | 2010-12-14 | 2017-08-22 | The Johns Hopkins University | Treatment of cognitive impairment in a subject with a neurological autoimmune disease |
| US9120837B2 (en) | 2012-01-06 | 2015-09-01 | Molecular Insight Pharmaceuticals | Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX |
| CN105025933B (zh) | 2013-01-14 | 2019-03-26 | 分子制药洞察公司 | 三嗪类放射性药物和放射性显影剂 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5143908A (en) | 1986-11-05 | 1992-09-01 | Merck & Co., Inc. | Antibacterial agents and potentiators of carbapenem antibiotics |
| US4927966A (en) * | 1987-06-04 | 1990-05-22 | The Research Foundation Of State University Of New York | 2-mercaptomethylglutaric acid derivatives |
| JPH0474197A (ja) | 1990-07-12 | 1992-03-09 | Naoyoshi Suzuki | 新規な免疫調整生理活性ペプチド |
| US6011021A (en) | 1996-06-17 | 2000-01-04 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| US5795877A (en) | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US5804602A (en) | 1996-06-17 | 1998-09-08 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| US6046180A (en) | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
| US6017903A (en) | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
| US6071965A (en) | 1996-06-17 | 2000-06-06 | Guilford Pharmaceuticals Inc. | Phosphinic alkanoic acid derivatives |
| US6025345A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US5977090A (en) | 1996-09-27 | 1999-11-02 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors |
| US6384022B1 (en) * | 1996-06-17 | 2002-05-07 | Guilford Pharmaceuticals Inc. | Prodrugs of NAALAdase inhibitors |
| US5824662A (en) | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
| US5863536A (en) | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
| US6054444A (en) | 1997-04-24 | 2000-04-25 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
| US5902817A (en) * | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
| US5672592A (en) | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
| US6025344A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Certain dioic acid derivatives useful as NAALADase inhibitors |
| ID18382A (id) * | 1996-09-27 | 1998-04-02 | Guilford Pharm Inc | Komposisi sediaan farmasi dan metoda pengobatan gangguan kompulsif dengan menggunakan inhibitor naaladase |
| US5962521A (en) | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
| EP1005348A1 (de) * | 1996-09-27 | 2000-06-07 | Guilford Pharmaceuticals Inc. | Naaladase zusammensetzungen und verfahren zur behandlung von glutamatabnormalien und der neuronalen aktivität in tieren |
| US5981209A (en) | 1997-12-04 | 1999-11-09 | Guilford Pharmaceuticals Inc. | Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia |
| US6028216A (en) * | 1997-12-31 | 2000-02-22 | Guilford Pharmaceuticals Inc. | Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives |
| US6121252A (en) | 1998-03-30 | 2000-09-19 | Guilford Pharmaceuticals Inc. | Phosphinic acid derivatives |
| CZ200113A3 (cs) * | 1998-07-06 | 2001-08-15 | Guilford Pharmaceuticals Inc. | Inhibitory NAALAdázy využitelné jako léčiva a farmaceutické kompozice, které je obsahují |
-
1999
- 1999-07-01 US US09/345,782 patent/US6228888B1/en not_active Expired - Fee Related
-
2000
- 2000-06-30 AT AT00943374T patent/ATE260653T1/de not_active IP Right Cessation
- 2000-06-30 EP EP00943374A patent/EP1202717B1/de not_active Expired - Lifetime
- 2000-06-30 MX MXPA02000255A patent/MXPA02000255A/es active IP Right Grant
- 2000-06-30 DE DE60008753T patent/DE60008753D1/de not_active Expired - Lifetime
- 2000-06-30 WO PCT/US2000/018260 patent/WO2001001974A2/en not_active Ceased
- 2000-06-30 JP JP2001507468A patent/JP2003503451A/ja active Pending
- 2000-06-30 AU AU57851/00A patent/AU5785100A/en not_active Abandoned
- 2000-06-30 CA CA002378467A patent/CA2378467A1/en not_active Abandoned
- 2000-12-21 US US09/741,169 patent/US6376478B1/en not_active Expired - Fee Related
-
2002
- 2002-02-20 US US10/077,877 patent/US20030013687A1/en not_active Abandoned
-
2005
- 2005-11-23 AU AU2005237108A patent/AU2005237108A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6228888B1 (en) | 2001-05-08 |
| EP1202717A2 (de) | 2002-05-08 |
| WO2001001974A2 (en) | 2001-01-11 |
| WO2001001974A3 (en) | 2002-03-07 |
| US6376478B1 (en) | 2002-04-23 |
| US20030013687A1 (en) | 2003-01-16 |
| AU5785100A (en) | 2001-01-22 |
| JP2003503451A (ja) | 2003-01-28 |
| ATE260653T1 (de) | 2004-03-15 |
| EP1202717B1 (de) | 2004-03-03 |
| MXPA02000255A (es) | 2002-06-21 |
| AU2005237108A1 (en) | 2005-12-15 |
| CA2378467A1 (en) | 2001-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60008753D1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| ATE362363T1 (de) | Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden | |
| DE69729125D1 (de) | Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese | |
| DE60029799D1 (de) | Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe | |
| DE69616376D1 (de) | Verwendung von Tiagabin zur Behandlung von Schlafstörungen | |
| ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| DE60112766D1 (de) | Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen | |
| ATE554169T1 (de) | Smad7-inhibitoren zur behandlung von krankheiten des zns | |
| ATE357438T1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| ATE275400T1 (de) | Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ | |
| ATE210447T1 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
| ATE367380T1 (de) | Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate | |
| ATE271861T1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
| DE60018704D1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| ATE255094T1 (de) | Piperazinderivate zur behandlung der niedrigen harnwege | |
| ATE281841T1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
| DE60005952T8 (de) | Lösliche hla-g enthaltende zusammensetzungen zur behandlung entzündlicher hautkrankheiten | |
| TR200200278T2 (tr) | Kalsilitik bileşimler | |
| HUP0103712A2 (hu) | Paroxetin sók, eljárás az előállításukra és gyógyászati alkalmazásuk | |
| DE60108130D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
| ATE330596T1 (de) | Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen | |
| ATE374197T1 (de) | Indolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| DE60220825D1 (de) | Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks | |
| JO2724B1 (en) | 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors | |
| ATE319709T1 (de) | Indolderivate zur behandlung von depression und angstzuständen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8332 | No legal effect for de |